ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
Clinical trial NCT05366062 · UNKNOWN
Trial details
- NCT number
- NCT05366062
- Sponsor
- Epitopoietic Research Corporation
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-01
- Primary completion
- 2025-07-31
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.